Streptonivicin (albamycin) : a new antibiotic; preliminary report
Martin, W.J.; Heilman, F.R.; Nichols, D.R.; Wellman, W.E.; Geraci, J.E.
Proceedings of the Staff Meetings. Mayo Clinic 30(23): 540-551
1955
ISSN/ISBN: 0092-699X PMID: 13273516 Document Number: 9953
Streptonivicin is a new antibiotic which in vitro and in vivo is very active against Micrococcus pyogenes. There apparently is no cross resistance between streptonivicin and penicillin, streptomycin, chloramphenicol, the tetracycline group of compounds, neomycin, bacitracin, .and erythromycin, and organisms resistant to them may be fully susceptible to streptonivicin. Laboratory evidence indicates that AI. pyogenes can become resistant to streptonivicin. Streptonivicin was effective in the treatment of an experimental infection with M. pyogenes in mice. The drug is bound extensively by serum proteins. Streptonivicin is absorbed into the general circulation when orally administered. Detectable levels in the serum after oral administration persist beyond 12 hours. These studies indicate that streptonivicin is distributed in blood, pleural and ascitic fluids, and thyroid tissue, and is excreted in the bile, urine and feces. Under the conditions of our study, streptonivicin was not detected in cerebrospinal fluid. It is hoped that these studies will prove of some value in the outline of treatment and interpretation of results which might be obtained after the use of streptonivicin in the treatment of infections owing to organisms susceptible to its action.
Document emailed within 1 workday
